- Home
- ASLE vs RGNX Comparison
ASLE vs RGNX Comparison
Compare ASLE & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASLE
- RGNX
- Stock Information
- Founded
- ASLE 2008
- RGNX 2008
- Country
- ASLE United States
- RGNX United States
- Employees
- ASLE N/A
- RGNX N/A
- Industry
- ASLE Industrial Specialties
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASLE Consumer Discretionary
- RGNX Health Care
- Exchange
- ASLE Nasdaq
- RGNX Nasdaq
- Market Cap
- ASLE 400.6M
- RGNX 451.1M
- IPO Year
- ASLE N/A
- RGNX 2015
- Fundamental
- Price
- ASLE $8.66
- RGNX $9.36
- Analyst Decision
- ASLE Hold
- RGNX Strong Buy
- Analyst Count
- ASLE 2
- RGNX 8
- Target Price
- ASLE $7.00
- RGNX $28.50
- AVG Volume (30 Days)
- ASLE 463.8K
- RGNX 489.2K
- Earning Date
- ASLE 11-06-2025
- RGNX 11-05-2025
- Dividend Yield
- ASLE N/A
- RGNX N/A
- EPS Growth
- ASLE N/A
- RGNX N/A
- EPS
- ASLE 0.13
- RGNX N/A
- Revenue
- ASLE $350,583,000.00
- RGNX $155,782,000.00
- Revenue This Year
- ASLE $9.98
- RGNX $203.27
- Revenue Next Year
- ASLE $8.15
- RGNX $0.58
- P/E Ratio
- ASLE $65.79
- RGNX N/A
- Revenue Growth
- ASLE N/A
- RGNX 74.95
- 52 Week Low
- ASLE $4.53
- RGNX $5.04
- 52 Week High
- ASLE $9.12
- RGNX $13.15
- Technical
- Relative Strength Index (RSI)
- ASLE 56.22
- RGNX 53.73
- Support Level
- ASLE $8.31
- RGNX $8.99
- Resistance Level
- ASLE $8.92
- RGNX $9.50
- Average True Range (ATR)
- ASLE 0.31
- RGNX 0.54
- MACD
- ASLE -0.08
- RGNX -0.04
- Stochastic Oscillator
- ASLE 66.23
- RGNX 48.75
About ASLE AerSale Corporation
AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.